Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-05-20

MacroGenics (MGNX)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$2,078,854
Eric Risser total, FY2025
33rd
CEO pay percentile vs peers
CEO-to-median pay ratio
98.06%
Say-on-pay support, latest vote
Companies that benchmark against MGNX
11 companies name MGNX as a compensation peer

Each company listed discloses MGNX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named MGNX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Eric Risser$561,568$150,000$52,000$1,049,386$251,900$0$14,000$2,078,854
President, Chief Executive Officer and Director
Ezio Bonvini533,200150,00054,600288,038184,200014,0001,224,038
Senior Vice President, Research and Chief Scientific Officer
James Karrels506,548150,00049,400254,284175,000014,0001,149,232
Senior Vice President and Chief Financial Officer
Scott Koenig477,12000000475,841952,961
Former Chief Executive Officer and current Director

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Eric Risser$2,078,854
Ezio Bonvini1,224,038
James Karrels1,149,2322,365,543−1,216,311
Scott Koenig952,9616,403,448−5,450,487

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Scott JacksonDirector2026-05-18D3,750$0$0Derivative, Class A CommonForm 4 ↗
Federica O'BrienDirector2026-05-18A3,750CommonForm 4 ↗
Federica O'BrienDirector2026-05-18A22,00000Derivative, Class A CommonForm 4 ↗
William HeidenDirector2026-05-18D3,75000Derivative, Class A CommonForm 4 ↗
William HeidenDirector2026-05-18A22,00000Derivative, Class A CommonForm 4 ↗
Margaret LiuDirector2026-05-18A3,750CommonForm 4 ↗
Meenu ChhabraDirector2026-05-18A22,00000Derivative, Class A CommonForm 4 ↗
Edward HurwitzDirector2026-05-18A3,75000Derivative, Class A CommonForm 4 ↗
Edward HurwitzDirector2026-05-18A22,00000Derivative, Class A CommonForm 4 ↗
Karen FerranteDirector2026-05-18A3,750CommonForm 4 ↗
Karen FerranteDirector2026-05-18D3,75000Derivative, Class A CommonForm 4 ↗
Scott JacksonDirector2026-05-18A3,750CommonForm 4 ↗
Margaret LiuDirector2026-05-18D3,75000Derivative, Class A CommonForm 4 ↗
Jay SiegelDirector2026-05-18D3,75000Derivative, Class A CommonForm 4 ↗
Margaret LiuDirector2026-05-18A22,00000Derivative, Class A CommonForm 4 ↗
Edward HurwitzDirector2026-05-18A3,750CommonForm 4 ↗
David StumpDirector2026-05-18A22,00000Derivative, Class A CommonForm 4 ↗
David StumpDirector2026-05-18A3,750CommonForm 4 ↗
Margaret LiuDirector2026-05-18A3,75000Derivative, Class A CommonForm 4 ↗
Federica O'BrienDirector2026-05-18D3,75000Derivative, Class A CommonForm 4 ↗
Federica O'BrienDirector2026-05-18A3,75000Derivative, Class A CommonForm 4 ↗
Meenu ChhabraDirector2026-05-18A3,75000Derivative, Class A CommonForm 4 ↗
Edward HurwitzDirector2026-05-18D3,75000Derivative, Class A CommonForm 4 ↗
David StumpDirector2026-05-18D3,75000Derivative, Class A CommonForm 4 ↗
Karen FerranteDirector2026-05-18A3,75000Derivative, Class A CommonForm 4 ↗
Karen FerranteDirector2026-05-18A22,00000Derivative, Class A CommonForm 4 ↗
Meenu ChhabraDirector2026-05-18A3,750CommonForm 4 ↗
David StumpDirector2026-05-18A3,75000Derivative, Class A CommonForm 4 ↗
Scott JacksonDirector2026-05-18A3,75000Derivative, Class A CommonForm 4 ↗
Scott JacksonDirector2026-05-18A22,00000Derivative, Class A CommonForm 4 ↗
William HeidenDirector2026-05-18A3,750CommonForm 4 ↗
William HeidenDirector2026-05-18A3,75000Derivative, Class A CommonForm 4 ↗
Jay SiegelDirector2026-05-18A3,750CommonForm 4 ↗
Meenu ChhabraDirector2026-05-18D3,75000Derivative, Class A CommonForm 4 ↗
Scott KoenigDirector2026-05-19A3,75000Derivative, Class A CommonForm 4 ↗
Scott KoenigDirector2026-05-19A22,00000Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Eric RisserRSU22,332$35,955
Ezio BonviniRSU22,33235,955
Ezio BonviniRSU16,66526,831
Eric RisserOption97,5002.6
James KarrelsOption91,8132.6
Ezio BonviniOption4,68810.15
Eric RisserRSU20,00032,200
Ezio BonviniRSU21,00033,810
James KarrelsOption45,00018.3
Eric RisserOption50,62518.3
James KarrelsRSU19,00030,590
James KarrelsOption8,75010.15
James KarrelsRSU14,99924,148
Ezio BonviniOption50,62518.3
Eric RisserOption550,0001.66
Eric RisserRSU16,66526,831
James KarrelsRSU19,99832,197
Eric RisserOption62,5004.82
Eric RisserOption10,62510.15
Ezio BonviniOption62,5004.82
James KarrelsOption56,2504.82
Ezio BonviniOption104,0002.6
05

Incentive-plan design — the Compensation Discussion & Analysis

MacroGenics executive compensation program, overseen by the Human Capital Management Committee, is designed to attract, retain and reward highly qualified talent at the senior executive level, in a very competitive market, while ensuring individual and corporate accountability to achieve the Company's mission, vision, and goals.

CEO STI target (% of salary)60%
CEO LTI target (% of salary)
Independent consultantAlpine Rewards, LLC
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-1926,624,952526,125195,22898.06%Passed
20252025-05-2142,433,2761,382,35617,65696.85%Passed
20242024-05-2149,530,2702,225,77912,17095.7%Passed
20232023-05-3143,633,4125,433,9607,83388.93%Passed
20222022-05-1944,883,7401,964,6578,17195.81%Passed
20212021-05-1348,895,8271,660,23721,80096.72%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-1998.06%a
20252025-05-2196.85%b
20242024-05-2195.7%c

a. Approved under the standard stated in the filing — “Abstentions are not considered votes cast and, therefore, will have no effect on the vote outcome.”.

b. Approved under the standard stated in the filing — “Abstentions are not considered votes cast and, therefore, will have no effect on the vote outcome.”.

c. Approved under the standard stated in the filing — “Abstentions are not considered votes cast and, therefore, will have no effect on the vote outcome.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)
CEO total compensation
Median employee compensation
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
William HeidenIndependent · Board Chair · Audit · Human Capital Management$118,125$5,587$21,318$0$145,030
Federica O'BrienIndependent · Audit (Chair) · Human Capital Management20,6255,58784,2650110,477
Jay SiegelIndependent · Human Capital Management · Science and Technology (Chair) · Not standing for re-election79,3755,58721,3180106,280
David StumpIndependent · Nominating/Governance (Chair) · Science and Technology68,9585,58721,318095,863
Margaret LiuIndependent · Nominating/Governance · Science and Technology58,9585,58721,318085,863
Edward HurwitzIndependent · Nominating/Governance · Science and Technology58,9585,58721,318085,863
Karen FerranteIndependent · Nominating/Governance · Science and Technology58,9585,58721,318085,863
Scott JacksonIndependent · Audit55,0005,58721,318081,905
Meenu Chhabra KarsonIndependent · Audit · Human Capital Management (Chair)5,6255,58769,005080,217
Scott KoenigIndependent16,875016,875
Eric RisserEmployee director00000
09

Board fee structure and ownership guideline

Annual cash retainer$45,000
Annual equity retainer$26,905
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)20,000 / 10,000
Stock ownership guideline3x annual retainer fees
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$541,457
Equity awards (grant-date value)$50,283
All other compensation$0
Total cost of the board$591,740

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies MacroGenics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including MacroGenics.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Cogent Biosciences2025Andrew Robbins$724,554$12,993,250$13,447,680$561,600$27,762,684
2Arcus Biosciences2025Terry Rosen775,0002,199,4506,008,860658,7509,656,813
3iTeos Therapeutics2024Michel Detheux628,68404,965,264421,0146,085,657
4Xencor, Inc.2025Bassil Dahiyat742,8001,552,8922,727,018490,2485,521,205
5Zymeworks, Inc.2024Kenneth Galbraith654,8332,112,0001,985,672361,6525,253,616
6Rigel Pharmaceuticals2025Raul Rodriguez787,405951,3272,241,570634,6494,658,805
7Y-mAbs Therapeutics2024Michael Rossi705,6001,170,7322,288,662392,5964,557,590
8Karyopharm Therapeutics2025Richard Paulson770,000838,996241,544350,3502,320,902
9Fate Therapeutics2025Bahram Valamehr600,00001,283,868360,0002,248,568
10Adaptimmune Therapeutics2024Adrian Rawcliffe676,00001,065,820324,4802,109,075
11MacroGenics2025Eric Risser561,56852,0001,049,386251,9002,078,854
12Mersana Therapeutics2024Michael Huber632,500133,635518,044322,5751,613,754
13Inovio Pharmaceuticals2025Jacqueline Shea728,000346,101351,955144,1441,587,155
14Agenus, Inc.2025Garo Armen715,2600141,00001,350,325
2seventy bionot in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
MacroGenics85%not disclosednot disclosedAlpine Rewards, LLC
2seventy bionot disclosednot disclosednot disclosednot disclosed
Adaptimmune Therapeutics80%Options 75 · RSU 25not disclosedPearl Meyer
Agenus, Inc.125%Options 100not disclosedAon Radford
Arcus Biosciences100%Options 67 · RSU 33not disclosedRadford
Cogent Biosciences135%not disclosedNoCompensia
Fate Therapeutics100%Options 100NoAon's Human Capital Solutions practice (Radford)
Inovio Pharmaceuticals33%not disclosedYes — Relative TSRAon (Human Capital Solutions practice)
iTeos Therapeuticsnot disclosednot disclosednot disclosedRadford
Karyopharm Therapeutics90%not disclosedYes — Relative TSRAlpine Rewards, LLC (through September 2025); Willis Towers Watson (beginning August 2025)
Mersana Therapeutics85%Options 75 · RSU 25not disclosedPearl Meyer & Partners, LLC
Rigel Pharmaceuticals124%Options 75 · RSU 25NoPearl Meyer
Xencor, Inc.110%Options 60 · RSU 40not disclosedAon
Y-mAbs Therapeutics85.6%PSU 34 · Options 33 · RSU 33NoAon's Human Capital Solutions practice (division of Aon plc)
Zymeworks, Inc.not disclosedOptions 50 · RSU 50not disclosedAon plc (Human Capital Solutions practice)

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Eric RisserDEF 14A2026-04-080001125345-26-000021Section “Summary Compensation Table”. As printed: 2,078,854. Filing ↗machine: r2 · c57 · span 494189–494198
2Section 01, Ezio BonviniDEF 14A2026-04-080001125345-26-000021Section “Summary Compensation Table”. As printed: 1,224,038. Filing ↗machine: r6 · c57 · span 506147–506156
3Section 01, James KarrelsDEF 14A2026-04-080001125345-26-000021Section “Summary Compensation Table”. As printed: 1,149,232. Filing ↗machine: r8 · c57 · span 510515–510524
4Section 01, Scott KoenigDEF 14A2026-04-080001125345-26-000021Section “Summary Compensation Table”. As printed: 952,961. Filing ↗machine: r4 · c57 · span 499138–499145
5Section 07, pay ratio10-K2026-03-090001125345-26-000017Section “CEO Pay Ratio”. As printed: —. Filing ↗
6Section 08, William HeidenDEF 14A2026-04-080001125345-26-000021Section “Director Compensation”. As printed: 145,030. Filing ↗machine: t6 · r3 · c9 · span 153246–153253
7Section 08, Federica O'BrienDEF 14A2026-04-080001125345-26-000021Section “Director Compensation”. As printed: 110,477. Filing ↗machine: t6 · r9 · c9 · span 163578–163585
8Section 08, Jay SiegelDEF 14A2026-04-080001125345-26-000021Section “Director Compensation”. As printed: 106,280. Filing ↗machine: t6 · r10 · c9 · span 165291–165298
9Section 08, David StumpDEF 14A2026-04-080001125345-26-000021Section “Director Compensation”. As printed: 95,863. Filing ↗machine: t6 · r11 · c9 · span 167005–167011
10Section 08, Margaret LiuDEF 14A2026-04-080001125345-26-000021Section “Director Compensation”. As printed: 85,863. Filing ↗machine: t6 · r8 · c9 · span 161862–161868
11Section 08, Edward HurwitzDEF 14A2026-04-080001125345-26-000021Section “Director Compensation”. As printed: 85,863. Filing ↗machine: t6 · r4 · c9 · span 154957–154963
12Section 08, Karen FerranteDEF 14A2026-04-080001125345-26-000021Section “Director Compensation”. As printed: 85,863. Filing ↗machine: t6 · r2 · c10 · span 151505–151511
13Section 08, Scott JacksonDEF 14A2026-04-080001125345-26-000021Section “Director Compensation”. As printed: 81,905. Filing ↗machine: t6 · r5 · c9 · span 156666–156672
14Section 08, Meenu Chhabra KarsonDEF 14A2026-04-080001125345-26-000021Section “Director Compensation”. As printed: 80,217. Filing ↗machine: t6 · r6 · c9 · span 158385–158391
15Section 08, Scott KoenigDEF 14A2026-04-080001125345-26-000021Section “Director Compensation”. As printed: 16,875. Filing ↗machine: t6 · r7 · c1 · span 159024–159030
16Section 08, Eric RisserDEF 14A2026-04-080001125345-26-000021Section “Director Compensation”. As printed: 0. Filing ↗
17Section 02, Scott Jackson 2026-05-18Form 42026-05-200001566617-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
18Section 02, Federica O'Brien 2026-05-18Form 42026-05-200001140119-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
19Section 02, Federica O'Brien 2026-05-18Form 42026-05-200001140119-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, William Heiden 2026-05-18Form 42026-05-200001214939-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, William Heiden 2026-05-18Form 42026-05-200001214939-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Margaret Liu 2026-05-18Form 42026-05-200001324059-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Meenu Chhabra 2026-05-18Form 42026-05-200001534200-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Edward Hurwitz 2026-05-18Form 42026-05-200001211840-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Edward Hurwitz 2026-05-18Form 42026-05-200001211840-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Karen Ferrante 2026-05-18Form 42026-05-200001598502-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Karen Ferrante 2026-05-18Form 42026-05-200001598502-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Scott Jackson 2026-05-18Form 42026-05-200001566617-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Margaret Liu 2026-05-18Form 42026-05-200001324059-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Jay Siegel 2026-05-18Form 42026-05-200001722857-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Margaret Liu 2026-05-18Form 42026-05-200001324059-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Edward Hurwitz 2026-05-18Form 42026-05-200001211840-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, David Stump 2026-05-18Form 42026-05-200001191235-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, David Stump 2026-05-18Form 42026-05-200001191235-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Margaret Liu 2026-05-18Form 42026-05-200001324059-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Federica O'Brien 2026-05-18Form 42026-05-200001140119-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Federica O'Brien 2026-05-18Form 42026-05-200001140119-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Meenu Chhabra 2026-05-18Form 42026-05-200001534200-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Edward Hurwitz 2026-05-18Form 42026-05-200001211840-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, David Stump 2026-05-18Form 42026-05-200001191235-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Karen Ferrante 2026-05-18Form 42026-05-200001598502-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Karen Ferrante 2026-05-18Form 42026-05-200001598502-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Meenu Chhabra 2026-05-18Form 42026-05-200001534200-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, David Stump 2026-05-18Form 42026-05-200001191235-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Scott Jackson 2026-05-18Form 42026-05-200001566617-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Scott Jackson 2026-05-18Form 42026-05-200001566617-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, William Heiden 2026-05-18Form 42026-05-200001214939-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, William Heiden 2026-05-18Form 42026-05-200001214939-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Jay Siegel 2026-05-18Form 42026-05-200001722857-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Meenu Chhabra 2026-05-18Form 42026-05-200001534200-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Scott Koenig 2026-05-19Form 42026-05-200001587514-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Scott Koenig 2026-05-19Form 42026-05-200001587514-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
53Section 06, 2026 voteForm 8-K2026-05-200001125345-26-000042Item 5.07 · say-on-pay result. As reported: 98.06% (votes for as printed: 26,624,952). Filing ↗
54Section 06, 2025 voteForm 8-K2025-05-220001125345-25-000075Item 5.07 · say-on-pay result. As reported: 96.85% (votes for as printed: 42,433,276). Filing ↗
55Section 06, 2024 voteForm 8-K2024-05-230001125345-24-000124Item 5.07 · say-on-pay result. As reported: 95.7% (votes for as printed: 49,530,270). Filing ↗
56Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
57Section 09b board cost (computed)ComputedcomputedCash 541,457 + equity 50,283 + all other 0 = 591,740, summed across the director compensation table rows.machine: formula: Σ = 591,740
58Cogent Biosciences, Section 10b CEO totalDEF 14A2026-04-230001193125-26-173834CEO total compensation as printed in Cogent Biosciences's own proxy. As printed: 27,762,684. Filing ↗machine: r2 · c39 · span 369353–369363
59Arcus Biosciences, Section 10b CEO totalDEF 14A2026-04-210001724521-26-000025CEO total compensation as printed in Arcus Biosciences's own proxy. As printed: 9,656,813. Filing ↗machine: r2 · c48 · span 403740–403749
60iTeos Therapeutics, Section 10b CEO totalDEF 14A2025-04-240000950170-25-057666CEO total compensation as printed in iTeos Therapeutics's own proxy. As printed: 6,085,657. Filing ↗machine: r2 · c27 · span 499272–499281
61Xencor, Inc., Section 10b CEO totalDEF 14A2026-04-270001326732-26-000031CEO total compensation as printed in Xencor, Inc.'s own proxy. As printed: 5,521,205. Filing ↗machine: t32 · r3 · c19 · span 631325–631334
62Zymeworks, Inc., Section 10b CEO totalDEF 14A2025-11-100001193125-25-274338CEO total compensation as printed in Zymeworks, Inc.'s own proxy. As printed: 5,253,616. Filing ↗machine: r2 · c30 · span 541437–541446
63Rigel Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-030001034842-26-000023CEO total compensation as printed in Rigel Pharmaceuticals's own proxy. As printed: 4,658,805. Filing ↗machine: t120 · r3 · c22 · span 886059–886068
64Y-mAbs Therapeutics, Section 10b CEO totalDEF 14A2025-05-300001558370-25-008299CEO total compensation as printed in Y-mAbs Therapeutics's own proxy. As printed: 4,557,590. Filing ↗machine: t100 · r5 · c23 · span 597595–597604
65Karyopharm Therapeutics, Section 10b CEO totalDEF 14A2026-04-130001503802-26-000023CEO total compensation as printed in Karyopharm Therapeutics's own proxy. As printed: 2,320,902. Filing ↗machine: r2 · c29 · span 1192339–1192348
66Fate Therapeutics, Section 10b CEO totalDEF 14A2026-04-240001193125-26-177094CEO total compensation as printed in Fate Therapeutics's own proxy. As printed: 2,248,568. Filing ↗machine: r2 · c31 · span 391551–391560
67Adaptimmune Therapeutics, Section 10b CEO totalDEF 14A2025-04-250001104659-25-039042CEO total compensation as printed in Adaptimmune Therapeutics's own proxy. As printed: 2,109,075. Filing ↗machine: r1 · c41 · span 814415–814424
68MacroGenics (subject), Section 10b CEO totalDEF 14A2026-04-080001125345-26-000021CEO total compensation as printed in MacroGenics's own proxy. As printed: 2,078,854. Filing ↗machine: r2 · c57 · span 494189–494198
69Mersana Therapeutics, Section 10b CEO totalDEF 14A2025-04-290001104659-25-040448CEO total compensation as printed in Mersana Therapeutics's own proxy. As printed: 1,613,754. Filing ↗machine: t16 · r1 · c41 · span 608188–608197
70Inovio Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-070001055726-26-000011CEO total compensation as printed in Inovio Pharmaceuticals's own proxy. As printed: 1,587,155. Filing ↗machine: r4 · c24 · span 548358–548367
71Agenus, Inc., Section 10b CEO totalDEF 14A2026-04-300001193125-26-197536CEO total compensation as printed in Agenus, Inc.'s own proxy. As printed: 1,350,325. Filing ↗machine: r2 · c21 · span 404620–404629
72Section 10a, Mersana Therapeutics reciprocityDEF 14A0001104659-25-040448Mersana Therapeutics's most recent proxy was read; its disclosed peer group does not include MacroGenics. Filing ↗
73Section 10a, Rigel Pharmaceuticals reciprocityDEF 14A0001034842-26-000023Rigel Pharmaceuticals names MacroGenics in its own disclosed peer group (read from its most recent proxy). Filing ↗
74Section 10a, Y-mAbs Therapeutics reciprocityDEF 14A0001558370-25-008299Y-mAbs Therapeutics names MacroGenics in its own disclosed peer group (read from its most recent proxy). Filing ↗
75Section 10a, Adaptimmune Therapeutics reciprocityDEF 14A0001104659-25-039042Adaptimmune Therapeutics names MacroGenics in its own disclosed peer group (read from its most recent proxy). Filing ↗
76Section 10a, Agenus, Inc. reciprocityDEF 14A0001193125-26-197536Agenus, Inc. names MacroGenics in its own disclosed peer group (read from its most recent proxy). Filing ↗
77Section 10a, Xencor, Inc. reciprocityDEF 14A0001326732-26-000031Xencor, Inc.'s most recent proxy was read; its disclosed peer group does not include MacroGenics. Filing ↗
78Section 10a, Cogent Biosciences reciprocityDEF 14A0001193125-26-173834Cogent Biosciences's most recent proxy was read; its disclosed peer group does not include MacroGenics. Filing ↗